KR20160002681A - 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 - Google Patents

골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 Download PDF

Info

Publication number
KR20160002681A
KR20160002681A KR1020157022203A KR20157022203A KR20160002681A KR 20160002681 A KR20160002681 A KR 20160002681A KR 1020157022203 A KR1020157022203 A KR 1020157022203A KR 20157022203 A KR20157022203 A KR 20157022203A KR 20160002681 A KR20160002681 A KR 20160002681A
Authority
KR
South Korea
Prior art keywords
fgfr3
polypeptide
skeletal
sfgfr3
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157022203A
Other languages
English (en)
Korean (ko)
Inventor
엘비르 구즈
Original Assignee
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르)
위니베르씨떼 뽈 싸바띠에 뚤루즈 3
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르), 위니베르씨떼 뽈 싸바띠에 뚤루즈 3 filed Critical 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르)
Publication of KR20160002681A publication Critical patent/KR20160002681A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157022203A 2013-01-16 2013-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 Withdrawn KR20160002681A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (1)

Publication Number Publication Date
KR20160002681A true KR20160002681A (ko) 2016-01-08

Family

ID=48289519

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157022203A Withdrawn KR20160002681A (ko) 2013-01-16 2013-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR1020217013228A Withdrawn KR20210054026A (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR1020157022078A Expired - Fee Related KR102249454B1 (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217013228A Withdrawn KR20210054026A (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
KR1020157022078A Expired - Fee Related KR102249454B1 (ko) 2013-01-16 2014-01-16 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드

Country Status (19)

Country Link
US (5) US20150344855A1 (enExample)
EP (2) EP2945967B1 (enExample)
JP (3) JP2016506914A (enExample)
KR (3) KR20160002681A (enExample)
CN (1) CN105121464B (enExample)
AU (2) AU2013373679A1 (enExample)
CA (2) CA2898415A1 (enExample)
DK (1) DK2945967T3 (enExample)
EA (2) EA201591324A1 (enExample)
ES (1) ES2796743T3 (enExample)
HU (1) HUE049556T2 (enExample)
IL (2) IL239810A0 (enExample)
MX (2) MX372787B (enExample)
PE (1) PE20151664A1 (enExample)
PL (1) PL2945967T3 (enExample)
PT (1) PT2945967T (enExample)
SG (2) SG11201505488XA (enExample)
SI (1) SI2945967T1 (enExample)
WO (2) WO2014111744A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017188696A1 (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PT3242888T (pt) * 2015-01-07 2020-12-28 Pfizer Armadilhas de fgfr3 solúveis para o tratamento de distúrbios do crescimento ósseo
HUE058734T2 (hu) * 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
BR112020005459A2 (pt) * 2017-09-20 2020-09-29 Pfizer Inc. tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3)
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL122473A (en) 1995-06-12 2003-11-23 Yeda Res & Dev Fgfr3 as a marker for mesenchymal skeletal progenitor cells
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DK1718756T3 (da) 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
ES2336832T3 (es) * 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008038287A2 (en) 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWING PROCEDURES USING EXTRACELLULAR FGFR4 DOMAINS
CA2780457A1 (en) 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
US20120328599A1 (en) 2010-01-14 2012-12-27 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
ES2932954T5 (en) 2012-07-24 2025-10-28 Univ Columbia Fgfr-tacc fusion proteins and methods thereof
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
PT3242888T (pt) 2015-01-07 2020-12-28 Pfizer Armadilhas de fgfr3 solúveis para o tratamento de distúrbios do crescimento ósseo
HUE058734T2 (hu) 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
BR112020005459A2 (pt) 2017-09-20 2020-09-29 Pfizer Inc. tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017188696A1 (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체

Also Published As

Publication number Publication date
AU2013373679A1 (en) 2015-08-13
SG11201505140XA (en) 2015-07-30
JP6995069B2 (ja) 2022-02-04
MX2019013857A (es) 2020-01-20
US10724014B2 (en) 2020-07-28
EA201591055A1 (ru) 2016-04-29
MX2015009142A (es) 2015-11-06
CN105121464B (zh) 2021-05-07
US20200199545A1 (en) 2020-06-25
PE20151664A1 (es) 2015-11-28
US20210032608A1 (en) 2021-02-04
SI2945967T1 (sl) 2020-10-30
US11702642B2 (en) 2023-07-18
CN105121464A (zh) 2015-12-02
CA2898415A1 (en) 2014-07-24
US11814654B2 (en) 2023-11-14
DK2945967T3 (da) 2020-07-13
PL2945967T3 (pl) 2020-11-16
KR20210054026A (ko) 2021-05-12
EP2945967B1 (en) 2020-04-15
SG11201505488XA (en) 2015-08-28
KR20150122136A (ko) 2015-10-30
EP2945967A1 (en) 2015-11-25
KR102249454B1 (ko) 2021-05-07
WO2014111467A1 (en) 2014-07-24
MX372787B (es) 2020-07-03
US20150353624A1 (en) 2015-12-10
PT2945967T (pt) 2020-05-28
JP2016506912A (ja) 2016-03-07
IL239810A0 (en) 2015-08-31
EP3736285A1 (en) 2020-11-11
EA201591324A1 (ru) 2016-01-29
JP2019107006A (ja) 2019-07-04
CA2896978A1 (en) 2014-07-24
AU2014206844A1 (en) 2015-07-16
IL239996A0 (en) 2015-08-31
JP2016506914A (ja) 2016-03-07
HK1217959A1 (zh) 2017-01-27
US20150344855A1 (en) 2015-12-03
WO2014111744A1 (en) 2014-07-24
US20210032607A1 (en) 2021-02-04
ES2796743T3 (es) 2020-11-30
HUE049556T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
US11702642B2 (en) Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP3967755B1 (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
RS53302B (sr) Alkalna fosfataza koja je usmerena na kosti, pribor i postupci upotrebe
US20180087119A1 (en) Crystallized oxalate decarboxylase and methods of use
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
HK40039498A (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK1217959B (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK40116513A (en) Methods of treating tissue calcification
HK40070846A (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
BR112017005986B1 (pt) Complexo que compreende um primeiro heterodímero e um segundo heterodímero, composição farmacêutica e uso do complexo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000